• Disclaimer
  • Privacy Policy
Media Coverage
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
Media Coverage
No Result
View All Result
Home Market coverage

Harpoon Therapeutics Raises $25 Million to Fund Ongoing Clinical Studies.

Gabriel Bello Obando by Gabriel Bello Obando
March 27, 2023
in Market coverage
0
Bull vs. Bear Market
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Harpoon Therapeutics, a clinical-stage immuno-oncology company, has closed a private placement of redeemable preferred stock and warrants to purchase common stock to confident institutional and other accredited investors for aggregate gross proceeds of $25 million. The financing round included participation from both new and existing investors, including New Leaf, Arix Bioscience, Invus, OrbiMed, and K2 HealthVentures.

The company intends to use the net proceeds to complete its ongoing Phase 1 clinical studies for two TriTAC® T cell engagers, HPN217 (BCMA) and HPN328 (DLL3). HPN217 is being studied in a Phase 1 trial for patients with relapsed and refractory multiple myeloma, while HPN328 is in a Phase 1/2 study for patients with various neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer.

The funds raised in the private placement will also be used for working capital and other general corporate purposes.

Harpoon Therapeutics is a clinical-stage biotech company developing novel T cell-engaging biologics for treating cancer and other diseases. Its TriTAC® platform is designed to harness the power of a patient’s immune system to attack cancer cells.

The financing round is expected to provide Harpoon with the financial resources it needs to continue the development of its innovative therapies. The company’s TriTAC® platform has shown promising results in preclinical and clinical studies, and the funding will enable the company to advance its research and development efforts.

The participation of new and existing investors in the financing round is a positive sign for Harpoon. It reflects the growing interest in the company’s innovative approach to cancer treatment. The funds raised in the private placement will enable Harpoon to advance its clinical programs and move closer to bringing its potentially life-saving therapies to market.

In conclusion, closing this private placement is a significant milestone for Harpoon Therapeutics and represents an important step forward in developing its TriTAC® platform. The funds raised will provide the company with the financial resources it needs to continue its research and development efforts and bring its potentially transformative therapies to needy patients.

The TriTAC® technology developed by Harpoon Therapeutics is a proprietary platform for creating T-cell engagers designed to direct a patient’s immune system to identify and eliminate cancer cells. The platform can potentially address a broad range of cancer types and is being evaluated in multiple clinical trials.

HPN217 is one of Harpoon’s most advanced product candidates and is being developed to treat multiple myeloma, a type of blood cancer that affects plasma cells. The drug is designed to redirect T cells to target BCMA (B cell maturation antigen)-expressing cancer cells. HPN328, on the other hand, is being developed to treat multiple neuroendocrine tumors, including small-cell lung cancer and neuroendocrine prostate cancer. The drug is designed to redirect T cells to target DLL3-expressing cancer cells.

Harpoon’s CEO, Gerald McMahon, expressed his excitement about the successful completion of the private placement and stated that the additional funding would help advance the company’s clinical programs and bring new therapies to cancer patients. The company is committed to developing innovative treatments for cancer patients and is rapidly growing its pipeline of TriTAC® product candidates.

The successful completion of the private placement is a positive development for Harpoon and highlights the strong investor interest in the company’s innovative approach to cancer treatment. As the company continues to advance its clinical programs, investors will be closely watching for updates on the progress of its product candidates and the potential impact they may have on cancer patients.

Tags: Harpoon
Previous Post

Canadian Crypto Companies Push Back Against Proposal to Treat Stablecoins as Securities

Next Post

US stock market sees mixed close with Dow and S&P higher while Nasdaq falls

Next Post
Money

US stock market sees mixed close with Dow and S&P higher while Nasdaq falls

Wealth

Sugarhill Ddot’s Net Worth: Inside The Career of the Rising Drill Rap Star

by Gabriel Bello Obando
November 10, 2023
0

When it comes to the hip-hop scene in America, there are a few names that stand out. However, one name...

Read more

From Telenovelas to Hollywood: Exploring Kate del Castillo Net Worth and Career Achievements

June 1, 2023

Adamari López Net Worth: An Inspirational Tale of Resilience Beyond The Screen

June 1, 2023

Simon Helberg Net Worth: A Multi-Talented Hollywood Star

June 1, 2023

Lillo Brancato Jr. Net Worth: From Stepping Stone to Scandal – A Look into his Career

June 1, 2023

Categories

  • Analyst Ratings
  • Business
  • Business news
  • Market coverage
  • Pre-IPO & Startups
  • Stock Markets
  • Wealth
  • World Economy

About Us

Our team of experienced journalists and industry experts is committed to providing you with the latest and most accurate information on a wide range of topics, from finance and technology to politics and the economy.

We are proud to be part of the Best Stocks team and to offer our readers exceptional content that is informed by our combined expertise. We look forward to continuing to serve our readers and to playing a key role in the world of business analysis and reporting.

READ MORE

  • Media Contacts
  • Journalist Contacts
  • Contact
  • About us
  • Disclaimer
  • Privacy Policy

© 2023 Media Coverage

No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact

© 2023 Media Coverage